Calidi Biotherapeutics ( (CLDI) ) just unveiled an update.
Calidi Biotherapeutics, Inc. announced FDA clearance for a clinical trial of its novel immunotherapy, CLD-101, in treating high-grade glioma. The Phase 1b/2 trial, set to begin in late 2024 at Northwestern University, will assess the safety and feasibility of administering multiple doses to patients with this aggressive brain cancer. Following promising results from a previous trial indicating safety and potential efficacy, this development marks a significant step in providing a new treatment option for a cancer with a low five-year survival rate.
See more insights into CLDI stock on TipRanks’ Stock Analysis page.
